This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results-
Anti-Cancer Mechanism of Trastuzumab via Blocking Nuclear HER2 Function and Epigenetic Mechanism of Resistance
DownloadSpring 2020
HER2 receptor tyrosine kinase (encoded by ERBB2 gene) is overexpressed in approximately 25% of all breast cancer tumors (known as HER2-positive breast cancers). Overexpression of HER2 causes overactivation of downstream receptor tyrosine kinase pathways including PI3K/Akt and MAPK pathways and is...
-
Fall 2020
Rac1 is a small GTPase that belongs to the Rho family. Like other Rho family GTPases, it mediates a plethora of cellular effects, including regulation of cytoarchitecture, cell size, cell adhesion, cell polarity, cell motility, proliferation, apoptosis/survival, and membrane trafficking. The...
-
Regulation of Epidermal Growth Factor Receptor Cell Signaling and Endocytosis during Mitosis
DownloadSpring 2018
EGFR-mediated signaling has been studied extensively since the 1980s due to its importance in several types of cancers. The majority of the research however has focused on the actions of the EGFR during G0/G1 and has neglected to characterize EGFR outside of this cell cycle phase. In this thesis,...
-
Understanding the Mode of Action of Trastuzumab to Design a Better Therapy for ErbB2-positive Human Breast Cancer
DownloadSpring 2016
Overexpression of ErbB2 occurs in about 25-30% of breast cancer cases and therefore, represents an attractive therapeutic target for treating breast cancer. There are two models for ErbB2 inhibitors that are currently in clinical use: humanized antibodies directed against ErbB2 and small molecule...